Eco Animal Health Group PLC EBT Share Purchase
October 14 2024 - 5:07AM
RNS Regulatory News
RNS Number : 0749I
Eco Animal Health Group PLC
14 October 2024
14 October 2024
ECO Animal Health Group
plc
("ECO" or
the "Company")
EBT Share Purchase
ECO Animal Health Group plc (AIM: EAH), a
rapidly growing global animal health company with a portfolio of
marketed veterinary products and a maturing proprietary R&D
pipeline, announces it has been notified that the trustees of the
ECO Animal Health Group EBT (the "EBT") have, on 11 October 2024
purchased 50,000 ordinary shares of 10p each in the Company
("Ordinary Shares") at a price of 72 pence per Ordinary
Share.
These Ordinary Shares are to be held in the EBT
and are intended to be used to satisfy the future vesting of share
options granted to employees of the Company. The EBT is a
discretionary trust for the benefit of the Company's employees,
including the Directors of the Company. The purchase of Ordinary
Shares by the EBT has been funded by a gift provided by the Company
from its existing cash resources.
Following this transaction, a total of 50,000
Ordinary Shares are held by the EBT, representing approximately
0.07 per cent. of the Company's total voting rights.
-Ends-
For further
information please contact:
ECO Animal
Health Group plc
David Hallas (CEO)
Christopher Wilks (CFO)
|
020 8447 8899
|
Singer Capital
Markets (Nominated Adviser & Joint Broker)
Phil Davies
Sam Butcher
|
020 7496 3000
|
Investec
(Joint Broker)
Gary Clarence
Lydia Zychowska
|
020 7597 5970
|
Equity
Development
Hannah Crowe
Matt Evans
|
020 7065 2692
|
ICR Consilium
(Financial PR)
Mary-Jane Elliott
Jessica Hodgson
|
020 3709 5700
ecoanimalhealth@consilium-comms.com
|
|
|
About ECO
Animal Health
ECO Animal Health is a world leader in animal
health, developing and marketing branded veterinary pharmaceuticals
globally, with expertise in antibiotics and vaccines for pigs and
poultry. We have a maturing proprietary R&D
pipeline.
Headquartered in the UK, with global
offices including R&D and manufacturing, we have marketing
authorisations in over 70 countries and employ over 200 people
worldwide.
Our lead product, Aivlosin® is a
proprietary, patented medication which is effective against both
respiratory and intestinal diseases in pigs and
poultry.
Click here for more information: https://ecoanimalhealth.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
MSCGPGBWUUPCUBC
Eco Animal Health (LSE:EAH)
Historical Stock Chart
From Nov 2024 to Dec 2024
Eco Animal Health (LSE:EAH)
Historical Stock Chart
From Dec 2023 to Dec 2024